Literature DB >> 24671500

Hyperleptinemia independent of body adiposity in women with fibromyalgia.

Diogo Homann1, Humberto Moreira Carvalho, Joice Mara Facco Stefanello, Suelen Meira Góes, André Luiz Lopes, Alvaro Reischak de Oliveira, Neiva Leite.   

Abstract

The prevalence of overweight and obesity in patients with fibromyalgia is high, which makes these patients more likely to trigger metabolic changes. It is also uncertain whether the clinical manifestations of fibromyalgia alter the metabolism in these patients. This study investigates the influence of adiposity indicators and presence of fibromyalgia on leptin and acylated ghrelin levels, which are hormones responsible for controlling energy homeostasis. Seventeen women with fibromyalgia (patients) and fifteen healthy women (controls) were evaluated. Pain intensity, physical activity level characteristics and leptin and acylated ghrelin levels were assessed. General linear models, using a main-effects model, were used to test the effect of fibromyalgia (patients vs. controls) on the relationship of leptin and acylated ghrelin with anthropometric indicators [body mass index, waist circumference (WC) and WC by height]. Patients showed higher leptin levels (controls: 9.1 ± 6.7 vs. patients: 22.4 ± 10.6 ng/mL; p < 0.01) and lower acylated ghrelin levels (controls: 188.7 ± 103.4 vs. patients: 126.7 ± 47.8 pg/mL; p = 0.04). The anthropometric variables, entered into linear models as independent variables, significantly influenced both leptin and acylated ghrelin levels (p < 0.01). The explained variance (R(2)) of the models containing leptin was higher (R(2) = 0.52-0.61) compared to the models containing acylated ghrelin (R(2) = 0.24-0.27). When analyzing the influence of the presence of fibromyalgia (study group: women with fibromyalgia vs. healthy women), only the leptin levels were influenced. High leptin levels independent of adiposity in women with fibromyalgia may be associated with the clinical condition of this syndrome.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24671500     DOI: 10.1007/s00296-014-2988-0

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  44 in total

1.  Ghrelin inhibits inflammatory pain in rats: involvement of the opioid system.

Authors:  Valeria Sibilia; Norma Lattuada; Daniela Rapetti; Francesca Pagani; DeLuca Vincenza; Ilaria Bulgarelli; Vittorio Locatelli; Francesca Guidobono; Carmela Netti
Journal:  Neuropharmacology       Date:  2006-06-08       Impact factor: 5.250

2.  Low plasma ghrelin concentration is an indicator of the metabolic syndrome.

Authors:  Olavi Ukkola; Seppo M Pöykkö; Y Antero Kesäniemi
Journal:  Ann Med       Date:  2006       Impact factor: 4.709

3.  Counterbalance between leptin and cortisol may be associated with fibromyalgia.

Authors:  Pieranna Fietta; Pierluigi Fietta
Journal:  Psychiatry Clin Neurosci       Date:  2006-08       Impact factor: 5.188

4.  Relationship between fibromyalgia and obesity in pain, function, mood, and sleep.

Authors:  Akiko Okifuji; Gary W Donaldson; Lynn Barck; Perry G Fine
Journal:  J Pain       Date:  2010-06-09       Impact factor: 5.820

5.  Growth hormone treatment for sustained pain reduction and improvement in quality of life in severe fibromyalgia.

Authors:  Guillem Cuatrecasas; C Alegre; J Fernandez-Solà; M J Gonzalez; F Garcia-Fructuoso; V Poca-Dias; A Nadal; Gabriel Cuatrecasas; F Navarro; A Mera; M Lage; R Peinó; F Casanueva; C Liñan; G Sesmilo; M J Coves; J P Izquierdo; I Alvarez; E Granados; M Puig-Domingo
Journal:  Pain       Date:  2012-03-31       Impact factor: 6.961

6.  Relationship between body mass index and fibromyalgia features.

Authors:  Muhammad B Yunus; Sule Arslan; Jean C Aldag
Journal:  Scand J Rheumatol       Date:  2002       Impact factor: 3.641

7.  High prevalence of growth hormone deficiency in severe fibromyalgia syndromes.

Authors:  G Cuatrecasas; M J Gonzalez; C Alegre; G Sesmilo; J Fernandez-Solà; F F Casanueva; F Garcia-Fructuoso; V Poca-Dias; J P Izquierdo; M Puig-Domingo
Journal:  J Clin Endocrinol Metab       Date:  2010-07-14       Impact factor: 5.958

8.  Acylated ghrelin: a potential marker for fibromyalgia?

Authors:  D Homann; F M Louzada; S M Góes; S Roizenblatt; A L Lopes; A R de Oliveira; N Leite
Journal:  Eur J Pain       Date:  2013-03-08       Impact factor: 3.931

9.  Spinal leptin contributes to the pathogenesis of neuropathic pain in rodents.

Authors:  Grewo Lim; Shuxing Wang; Yi Zhang; Yinghong Tian; Jianren Mao
Journal:  J Clin Invest       Date:  2009-01-12       Impact factor: 14.808

10.  Musculoskeletal pain in the obese: a comparison with a general population and long-term changes after conventional and surgical obesity treatment.

Authors:  Markku Peltonen; Anna Karin Lindroos; Jarl S Torgerson
Journal:  Pain       Date:  2003-08       Impact factor: 6.961

View more
  3 in total

1.  Ictal adipokines are associated with pain severity and treatment response in episodic migraine.

Authors:  Nu Cindy Chai; Bizu Gelaye; Gretchen E Tietjen; Paul D Dash; Barbara A Gower; Linda W White; Thomas N Ward; Ann I Scher; B Lee Peterlin
Journal:  Neurology       Date:  2015-03-06       Impact factor: 9.910

2.  Fibromyalgia syndrome and small fiber, early or mild sensory polyneuropathy.

Authors:  Victoria H Lawson; Jessie Grewal; Kevin V Hackshaw; Phillip C Mongiovi; Amro M Stino
Journal:  Muscle Nerve       Date:  2018-04-26       Impact factor: 3.217

3.  The relationship between serum leptin level and disease activity and inflammatory markers in fibromyalgia patients.

Authors:  Safinaz Ataoglu; Handan Ankarali; Rumeysa Samanci; Mustafa Ozsahin; Ozlem Admis
Journal:  North Clin Istanb       Date:  2018-04-16
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.